alert icon Coronavirus
Now scheduling COVID-19 vaccines for ages 5+, boosters and third doses
Schedule your appointment
COVID-19 vaccine FAQs

Going to a Cleveland Clinic location?
New visitation guidelines
Masks required for patients and visitors (even if you're vaccinated)

Daniel Farkas, PhD

Daniel Farkas, PhD
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Department Laboratory Medicine
Primary Location Cleveland Clinic Main Campus
Type of Doctor Adults Only
Languages English
Surgeon No
Locations
Insurance

Insurance

Is Cleveland Clinic Part of Your Insurance?

Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.

View All Plans
Biography

About Daniel Farkas, PhD

Daniel H. Farkas, PhD, HCLD (ABB), CC, CLSp(MB), FACB, is Section Head of Molecular Pathology at the Cleveland Clinic and on the faculty of the Cleveland Clinic Lerner College of Medicine. Prior to that he was Chief Clinical Laboratory Officer for Celmatix in New York City where he established its CLIA-certified, CAP-accredited genomics-of-infertility laboratory. Prior to Celmatix, Dr. Farkas was the lead laboratory director for Sequenom Laboratories with facilities in Morrisville, NC; San Diego, CA; and Grand Rapids, MI and oversaw these molecular diagnostics laboratories committed to maternal fetal medicine. Previously, Dr. Farkas had been Executive Director of the Center for Molecular Medicine in Grand Rapids, a collaborative genomics initiative between Spectrum Health and the Van Andel Institute. Dr. Farkas has established three hospital-based molecular diagnostics laboratories (St. Barnabas Medical Center, Livingston, NJ; Beaumont Hospital, Royal Oak, MI; and The Methodist Hospital, Houston, TX) and done two stints in the biotechnology industry. Dr. Farkas served on the American Association for Clinical Chemistry Board of Directors from 2007-2009 and has served on three College of American Pathologists Committees, notably for nine years on the Molecular Pathology Resource Committee and currently on the Molecular Oncology Committee. Dr. Farkas was the first professional certified by the American Board of Bioanalysis (ABB) in Molecular Diagnostics (1996) and served six years on ABB's board. Dr. Farkas has been President of the Association for Molecular Pathology (AMP), its Program Chair, and is a past AMP Leadership Award winner. He is a member of the FDA Clinical and Molecular Genetics Devices Panel. He has been on the faculties of Michigan State University (MSU), Baylor College of Medicine, Weill Medical College of Cornell University, and Beaumont Hospital's Medical Technology program. Dr. Farkas earned a BS degree in Microbiology and Public Health from MSU and a PhD in Cellular and Molecular Biology from the State University of New York at Buffalo. Dr. Farkas has lectured internationally and published widely on molecular diagnostics, including his latest book: “DNA From A to Z and Back Again.”

Education & Professional Highlights

Education & Professional Highlights

Appointed
2016

Education & Fellowships

Residency - Monsanto Environmental Health Laboratory
St. Louis, MO USA
1989

Graduate School - SUNY Buffalo
Cellular & Molecular Biology
Buffalo, NY USA
1987

Undergraduate - Michigan State University
Microbiology/Public Health
East Lansing, MI USA
1979

Professional Highlights

  • President, Association for Molecular Pathology, 2003

Specialty Interests

Molecular Diagnostics, Precision Medicine, Genomics

Awards & Honors

  • Association for Molecular Pathology Leadership Award Winner, 2007
Research & Publications

Research & Publications

See publications for Daniel Farkas, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 8/19/2021, Dr. Farkas has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Related Videos Featuring Daniel Farkas, PhD

Related Videos Featuring Daniel Farkas, PhD

Back to Top